Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  The Lancet

• Publication date

  1995-01-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(95)91150-2PMID 7799740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.

  1994cited by this paper
• Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

  1994cited by this paper
• Using T cells to treat B-cell cancers.

  1994cited by this paper
• Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.

  1994cited by this paper
• Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease.

  1994cited by this paper
• Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.

  1994cited by this paper
• Epstein-Barr virus strategy in normal and neoplastic B cells.

  1994cited by this paper
• An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease

  1994cited by this paper
• Epstein-Barr infection after bone marrow transplantation.

  1994cited by this paper
• Donor T cells to treat EBV-associated lymphoma.

  1994cited by this paper
• Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management

  1993cited by this paper
• Epstein-Barr virus in lymphomas: a review.

  1993cited by this paper
• NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management.

  1993cited by this paper
• Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients.

  1993cited by this paper
• Epstein-Barr virus, lymphomas and Hodgkin's disease.

  1992cited by this paper
• Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

  1992cited by this paper
• Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1).

  1992cited by this paper
• Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

  1992cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.

  1991cited by this paper
• Epstein‐Barr Virus Lymphoproliferative Disease Associated with Acquired Immunodeficiency

  1991cited by this paper
• Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

  1991cited by this paper
• Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.

  1991cited by this paper
• Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

  1990cited by this paper
• Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients

  1990cited by this paper
• Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

  1989cited by this paper
• Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus.

  1987cited by this paper
• Geographical prevalence of two types of Epstein-Barr virus.

  1986cited by this paper
• Epstein-Barr virus infection and immunity in bone marrow transplant recipients.

  1986cited by this paper
• Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients.

  1984cited by this paper
• Long-term T-cell-mediated immunity to Epstein-Barr virus.

  1981cited by this paper
• Long‐term T‐cell‐mediated immunity to epstein‐barr virus in man. IV. Development of T‐cell memory in convalescent infectious mononucleosis patients

  1980cited by this paper

• Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders

  2026cites this paper
• A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures

  2026cites this paper
• Posttransplant EBV‐Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi‐Institution Experience

  2025cites this paper
• Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas

  2025cites this paper
• Adoptive T-cell therapy for virus-associated diseases

  2025cites this paper
• Effective management of primary central nervous system posttransplant lymphoproliferative disorder in a kidney transplant recipient using surgery and rituximab, along with a literature review.

  2025cites this paper
• Adoptive T‐cell therapies in the clinic

  2025cites this paper
• Long-term efficacy of EBV-specific T cells for EBV-PTLD after allogeneic stem cell transplantation: a real word study.

  2025cites this paper
• Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context

  2025cites this paper
• A Phase I Study Evaluating Safety and Tolerability of Viral‐Specific T Cells Against BK‐Virus in Adult Kidney Transplant Recipients

  2025cites this paper
• Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing.

  2025cites this paper
• Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?

  2025cites this paper
• Cellular Therapies in Transplantation – Regulatory T Cell Therapies and Virus Specific Therapies

  2025cites this paper
• Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation.

  2024cites this paper
• Prophylactic VSTs: a promising start but still work to do

  2024cites this paper
• EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management

  2024cites this paper
• Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses

  2024cites this paper
• Virus Specific T Cell Therapy to Treat Refractory Viral infections in Solid Organ Transplant Recipients.

  2024cites this paper
• A bibliometric study of the nasopharyngeal cancer immunotherapy knowledge map

  2024cites this paper
• MHC tetramer technology: Exploring T cell biology in health and disease.

  2024cites this paper
• Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo

  2024cites this paper
• Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review.

  2024cites this paper
• Targeting latent viral infection in EBV-associated lymphomas

  2024cites this paper
• Coinfection of EBV with other pathogens: a narrative review

  2024cites this paper
• Treatment of Epstein-Barr Virus infection in immunocompromised patients.

  2024cites this paper
• Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation

  2024cites this paper
• Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised

  2024cites this paper
• Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years

  2024cites this paper
• Applications of cell therapy in the treatment of virus-associated cancers

  2024cites this paper
• Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies

  2024cites this paper
• Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.

  2024cites this paper
• The ‘Oma’s of the Gammas—Cancerogenesis by γ-Herpesviruses

  2024cites this paper
• Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment

  2024cites this paper
• Adoptive cellular therapy after hematopoietic stem cell transplantation

  2024cites this paper
• Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma

  2024cites this paper
• Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients.

  2024cites this paper
• EBV-induced T-cell responses in EBV-specific and nonspecific cancers

  2023cites this paper
• Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond

  2023cites this paper
• Clinical Trials of Cellular Therapies in Solid Tumors

  2023cites this paper
• Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice

  2023cites this paper
• Prevention and management of CMV infection in pediatric solid organ transplant recipients

  2023cites this paper
• Post-transplant malignancy: Focusing on virus-associated etiologies, pathogenesis, evidence-based management algorithms, present status of adoptive immunotherapy and future directions

  2023cites this paper
• Epstein‒Barr virus-associated cellular immunotherapy.

  2023cites this paper
• Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphoma

  2023cites this paper
• [Can academic structures improve access to CAR-T cells?]

  2023cites this paper
• Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma

  2023cites this paper
• How I Treat Post-Transplant Lymphoproliferative Disorder.

  2023cites this paper
• Screening and Management of PTLD

  2023cites this paper
• Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein–Barr Virus-Specific T-Cells

  2023cites this paper
• Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review

  2023cites this paper
• Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein–Barr Virus-Associated Malignancies

  2022cites this paper
• THE GENERATION AND APPLICATION OF ANTIGEN-SPECIFIC T CELL THERAPIES FOR CANCER AND VIRAL-ASSOCIATED DISEASE.

  2022cites this paper
• EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management

  2022cites this paper
• Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.

  2022cites this paper
• Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

  2022cites this paper
• Improving the safety of iPSC-derived T cell therapy

  2022cites this paper
• Applications of virus-specific T cell therapies post-BMT.

  2022cites this paper
• Virus-Specific T Cells: Promising Adoptive T Cell Therapy Against Infectious Diseases Following Hematopoietic Stem Cell Transplantation

  2022cites this paper
• EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy.

  2022cites this paper
• EBV-associated diseases: Current therapeutics and emerging technologies

  2022cites this paper
• A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell transfer applications

  2022cites this paper
• 造血干细胞移植后EB病毒相关淋巴增殖性疾病中国专家共识（2022年版）

  2022cites this paper
• Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients

  2022cites this paper
• Host-directed immunotherapy to fight infectious diseases

  2022cites this paper
• Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing

  2022cites this paper
• Facts and hopes in the relationship of EBV with cancer immunity and immunotherapy.

  2022cites this paper
• Viral Agents as Potential Drivers of Diffuse Large B-Cell Lymphoma Tumorigenesis

  2022cites this paper
• Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment.

  2022cites this paper
• Chapter XX Antiviral Treatment and Cancer Control.

  2021cites this paper
• Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

  2021cites this paper
• Virus-specific T cells for malignancies – then, now and whereto?

  2021influential citation
• Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

  2021cites this paper
• iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma

  2021cites this paper
• EBV+ Lymphoproliferative Diseases: Opportunities for leveraging EBV as a Therapeutic Target.

  2021cites this paper
• Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

  2021cites this paper
• Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment

  2021cites this paper
• Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

  2021cites this paper
• Advances in Cellular Immunotherapy in Hematologic Malignancies

  2021cites this paper
• Management of PTLD After HSCT

  2021cites this paper
• Immune Cells and Immunotherapy for Cardiac Injury and Repair

  2021cites this paper
• Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads

  2021cites this paper
• Advances in Adoptive Cell Therapy for Head and Neck Cancer.

  2021cites this paper
• Role of Virus-Specific T Cell Therapy for Cytomegalovirus and BK Infections in Kidney Transplant Recipients.

  2021cites this paper
• Management of PTLD after SOT

  2021cites this paper
• Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge

  2021cites this paper
• Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

  2021cites this paper
• Adoptive Transfer of JC Virus‐Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy

  2021cites this paper
• Prevention of Epstein-Barr Virus Infection and PTLD following SOT

  2021cites this paper
• Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art

  2021cites this paper
• Complete dynamical analysis for a nonlinear HTLV-I infection model with distributed delay, CTL response and immune impairment

  2020cites this paper
• Developing cell therapies as drug products

  2020cites this paper
• Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells

  2020cites this paper
• A 21st Century Evil: Immunopathology and New Therapies of COVID-19

  2020cites this paper
• ТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК ПАЦИЕНТАМ С ПЕРВИЧНЫМИ ИММУНОДЕФИЦИТАМИ ОТ АЛЬТЕРНАТИВНОГО ДОНОРА С ИСПОЛЬЗОВАНИЕМ НОВЫХ ТЕХНОЛОГИЙ ИНЖИНИРИНГА ТРАНСПЛАНТАТА

  2020cites this paper
• Post-Transplant Lymphoproliferative Disorders Arising after Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Review

  2020cites this paper
• Adoptive immunotherapy with antiviral T cells: Materials and methods

  2020cites this paper
• MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.

  2020cites this paper
• Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas

  2020cites this paper
• Childhood Lymphoma

  2020cites this paper
• Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives

  2020cites this paper